T1	intervention 0 9	Tamoxifen
T2	control 71 78	placebo
T3	No-of-participants 329 332	119
T4	eligibility 333 370	postmenopausal breast cancer patients
T5	duration 387 417	from August 1987 to March 1995
T6	average-age 564 575	35-70 years
T7	duration 592 622	from November 1993 to May 1996
T8	duration 771 778	5 years
T9	average-age 810 826	66 years (54-85)
T10	average-age 855 871	53 years (37-69)
T11	adverse-effect 1023 1109	hot flashes, vaginal discharge and/or bleeding, bone marrow depression and weight gain
T12	outcome 1255 1280	Temporary discontinuation
T13	intervention-value 1293 1297	2.5%
T14	control-value 1341 1345	5.4%
T15	outcome 1428 1453	Permanent discontinuation
T16	control-value 1528 1533	26.7%
T17	intervention-value 1537 1542	15.1%
